For more information on how semaglutide can fit into your personalized health regimen, visit our detailed service page here
Natural formulation, produced in HR
In all three studies, adults with obesity or overweight with at least one weight-related comorbidity were randomly assigned to once-weekly subcutaneous tirzepatide or placebo for 72 weeks
This important collaboration between Eccogene and AstraZeneca will accelerate the development of ECC5004, a once daily, low dose, orally available small molecule GLP-1RA to benefit the millions of patients worldwide living with these diseases." Sharon Barr, Executive Vice President, BioPharmaceuticals R&D at AstraZeneca, said: "With the number of people living with cardiometabolic conditions and obesity today already over one billion, there is a need for continued innovation and next generation therapeutic options
In vitro models of the blood-brain barrier for the study of drug delivery to the brain
Vnn1 pantetheinase limits the Warburg effect and sarcoma growth by rescuing mitochondrial activity
